Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.0K | $45.0K | $47.0K | $2.20M | $605K | $934K | $240K | $622K | $14.7M | $113M |
| Revenue growth | — | 2.3% | 4.4% | 4585.1% | -72.5% | 54.4% | -74.3% | 159.2% | 2270.6% | 668.3% |
| Operating income | -$125M | -$99.1M | -$98.4M | -$156M | -$221M | -$330M | -$351M | -$362M | -$344M | -$256M |
| Operating margin | -282954.5% | -220266.7% | -209338.3% | -7095.9% | -36509.1% | -35361.9% | -146374.2% | -58239.5% | -2334.2% | -226.0% |
| Net income | -$121M | -$96.4M | -$96.2M | -$158M | -$222M | -$347M | -$417M | -$583M | -$414M | -$351M |
| Net margin | -274565.9% | -214273.3% | -204736.2% | -7165.2% | -36669.6% | -37129.6% | -173569.6% | -93761.4% | -2804.8% | -310.2% |
| EPS (diluted) | -$1.47 | -$1.20 | -$1.22 | -$0.43 | -$0.59 | -$0.89 | -$1.04 | -$1.15 | -$0.62 | -$0.38 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$38.6M | -$48.8M | -$63.4M | -$152M | -$172M | -$274M | -$338M | -$367M | -$391M | -$305M |
| Capital expenditures | $6.56M | $34.8M | $13.1M | $4.29M | $1.67M | $33.6M | $78.2M | $30.6M | $6.89M | $3.85M |
| Free cash flow | -$45.2M | -$83.6M | -$76.5M | -$156M | -$173M | -$308M | -$416M | -$397M | -$398M | -$309M |
| Share buybacks | $15.8M | $15.2M | $228K | $2.50M | $0.00 | $0.00 | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $8.08M | $23.9M | $16.8M | $75.8M | $34.9M | $181M | $105M | $265M | $143M | $88.3M |
| Total assets | $317M | $250M | $182M | $143M | $221M | $469M | $362M | $504M | $383M | $502M |
| Total liabilities | $24.1M | $31.6M | $35.9M | $22.4M | $340M | $713M | $812M | $1.09B | $871M | $1.00B |
| Shareholders' equity | $293M | $219M | $146M | $121M | -$120M | -$242M | -$447M | -$587M | -$489M | -$500M |
| Retained earnings | -$387M | -$499M | -$595M | -$662M | -$1.62B | -$1.96B | -$2.38B | -$2.96B | -$3.38B | -$3.73B |
| Shares (wtd avg diluted) | 82.0M | 79.0M | 79.1M | 366M | 377M | 389M | 400M | 509M | 700M | 920M |
Every figure is extracted from ImmunityBio, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.